Curated News
By: NewsRamp Editorial Staff
July 18, 2024
Clene Inc. to Present at 73rd Emerging Growth Conference
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Investors can gain insight from Clene's presentation at the Emerging Growth Conference on July 18, 2024.
- Clene is a biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.
- Clene's research aims to improve the treatment of neurodegenerative diseases, potentially enhancing the quality of life for patients.
- CNM-Au8(R) is an investigational first-in-class therapy that targets mitochondrial function and the NAD pathway to improve central nervous system cells' survival and function.
Impact - Why it Matters
This news matters as it highlights Clene's efforts to develop innovative therapies for neurodegenerative diseases. The presentation at the conference provides an opportunity for investors and stakeholders to gain insights into the company's progress and future prospects in the biopharmaceutical industry.
Summary
Clene (NASDAQ: CLNN) and its subsidiary Clene Nanomedicine Inc. are set to present at the 73rd Emerging Growth Conference to discuss their focus on improving mitochondrial health and treating neurodegenerative diseases. The presentation will be given by Rob Etherington, Clene’s President and CEO, and Morgan Brown, Clene’s CFO.
The company is a late clinical-stage biopharmaceutical company, with a focus on developing therapies for diseases such as amyotrophic lateral sclerosis and multiple sclerosis. Their investigational therapy, CNM-Au8(R), targets mitochondrial function and the NAD pathway while reducing oxidative stress.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Inc. to Present at 73rd Emerging Growth Conference
